FDA approves Amgen's rituximab
Amgen's newly approved rituximab-arrx, a biosimilar version of
Genentech and Biogen's Rituxan, will be priced at $3,584 for a 500-mg
single-dose vial, representing a 23.7% discount off the reference product's
list price, an Amgen news release said.
Full Story: Healio
(free registration) (12/17)
No comments:
Post a Comment